<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mabwell (shanghai) Bioscience Co. Ltd. A — News on 6ix</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a</link>
<description>Latest news and press releases for Mabwell (shanghai) Bioscience Co. Ltd. A on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 07:02:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mabwell-shanghai-bioscience-co-ltd-a" rel="self" type="application/rss+xml" />
<item>
<title>2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/2026-asco-or-mabwell-to-present-latest-clinical-data-on-9mw2821-combined-with-toripalimab-for-urothelial-carcinoma-in-oral-and-poster-presentations</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/2026-asco-or-mabwell-to-present-latest-clinical-data-on-9mw2821-combined-with-toripalimab-for-urothelial-carcinoma-in-oral-and-poster-presentations</guid>
<pubDate>Thu, 23 Apr 2026 07:02:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA from May 29 to June 2, 2026 (local time), as an oral presentation and a poster presentation, respectively.</description>
</item>
<item>
<title>Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-patient-dosed-140000232</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-patient-dosed-140000232</guid>
<pubDate>Thu, 22 Jan 2026 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in a clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for the treatment of advanced colorectal cancer and other advanced gastrointestinal tumors.</description>
</item>
<item>
<title>Mabwell's Adalimumab Biosimilar Receives Marketing Approval in Indonesia</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwells-adalimumab-biosimilar-receives-marketing-140000444</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwells-adalimumab-biosimilar-receives-marketing-140000444</guid>
<pubDate>Wed, 31 Dec 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its Adalimumab Injection 9MW0113 (Marketed as JUNMAIKANG in China) has been granted marketing authorization by the Indonesian Food and Drug Authority (Badan Pengawas Obat dan Makanan, BPOM). This marks the third overseas marketing approval obtained by Mabwell so far this year.</description>
</item>
<item>
<title>Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-patient-dosed-140000226</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-patient-dosed-140000226</guid>
<pubDate>Tue, 30 Dec 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scarring recently completed the first patient dosing in China, becoming the world's first IL-11 targeting drug candidate to initiate clinical trials for pathological scarring.</description>
</item>
<item>
<title>Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-receives-ind-clearance-novel-140000983</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-receives-ind-clearance-novel-140000983</guid>
<pubDate>Wed, 24 Dec 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its self-developed anti-ST2 monoclonal antibody (R&D code: 9MW1911) to initiate a Phase IIa clinical study in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).</description>
</item>
<item>
<title>Mabwell Announces First Overseas Commercial Shipment of Denosumab Injection</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-overseas-commercial-140000591</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-overseas-commercial-140000591</guid>
<pubDate>Tue, 16 Dec 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovative biopharmaceutical company with an integrated industry chain, announced that it has completed the first commercial shipment of its Denosumab Injection to the overseas market. This delivery marks the official entry of the product into clinical application overseas and represents a major step in the company's globalization strategy.</description>
</item>
<item>
<title>Annualized Severe COPD Exacerbation Rate Reduced by Over 40%: Mabwell Announces Phase IIa Results for Innovative Anti-ST2 Antibody 9MW1911</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/annualized-severe-copd-exacerbation-rate-140000018</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/annualized-severe-copd-exacerbation-rate-140000018</guid>
<pubDate>Mon, 01 Dec 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the completion of its Phase IIa clinical study for 9MW1911, a self-developed anti-ST2 monoclonal antibody, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).</description>
</item>
<item>
<title>Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-patient-dosing-140000756</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-patient-dosing-140000756</guid>
<pubDate>Tue, 25 Nov 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for advanced solid tumors.</description>
</item>
<item>
<title>Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwells-novel-anti-il-11-140000261</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwells-novel-anti-il-11-140000261</guid>
<pubDate>Tue, 11 Nov 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China National Medical Products Administration (NMPA) to initiate a Phase II clinical trial for pathological scarring. 9MW3811 becomes the world's first IL‑11‑targeting therapeutic to enter clinical stage for this indication.</description>
</item>
<item>
<title>Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-latest-clinical-results-160000366</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-latest-clinical-results-160000366</guid>
<pubDate>Tue, 14 Oct 2025 16:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2025.</description>
</item>
<item>
<title>Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwells-cdh17-targeting-adc-7mw4911-120000016</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwells-cdh17-targeting-adc-7mw4911-120000016</guid>
<pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) in China to initiate clinical study in patients with advanced solid tumors.</description>
</item>
<item>
<title>Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-bioscience-aditum-bio-announce-120000523</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-bioscience-aditum-bio-announce-120000523</guid>
<pubDate>Wed, 17 Sep 2025 12:00:00 GMT</pubDate>
<description>Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease (ASCVD) events. Aditum Bio will provide funding for Kalexo Bio, and the parties will collaborate to advance 2MW7141 into clinical</description>
</item>
<item>
<title>Mabwell Secures Pakistan's First Denosumab Injection Approval</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-secures-pakistans-first-denosumab-143000754</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-secures-pakistans-first-denosumab-143000754</guid>
<pubDate>Fri, 05 Sep 2025 14:30:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, and Pakistan's The Searle Company Limited (PSX: SEARL, hereinafter "Searle") jointly announced that two denosumab products, 9MW0311 and 9MW0321, have received marketing authorization from Drug Regulatory Authority of Pakistan (DRAP). This marks both Pakistan's first regulatory approval for a denosumab biosimilar and Mabwell's first overseas marketing authorization for its products.</description>
</item>
<item>
<title>Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwells-cdh17-targeting-adc-7mw4911-140000157</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwells-cdh17-targeting-adc-7mw4911-140000157</guid>
<pubDate>Tue, 19 Aug 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the U.S. Food and Drug Administration (FDA). The clearance enables the initiation of Phase I/II study of 7MW4911 to evaluate the safety, pharmacokinetics, and efficacy in patients with advanced colorectal cancer and other advanced gastrointestinal tumors.</description>
</item>
<item>
<title>Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-patient-dosed-140000632</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-first-patient-dosed-140000632</guid>
<pubDate>Tue, 12 Aug 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced the first patient dosing in the U.S. for a clinical study of its novel nectin-4-targeting antibody-drug conjugate (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) in triple-negative breast cancer (TNBC) patients previously treated with antibody-drug conjugate (ADC). This is the first overseas clinical study of 9MW2821, representing a significant step in Mabwell's global development of ADC therapeu</description>
</item>
<item>
<title>Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-ind-application-acceptance-140000996</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-ind-application-acceptance-140000996</guid>
<pubDate>Fri, 01 Aug 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance from China's National Medical Products Administration (NMPA) and an IND Acknowledgement Letter from the U.S. Food and Drug Administration (FDA).</description>
</item>
<item>
<title>Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-novel-drug-technology-140000921</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-novel-drug-technology-140000921</guid>
<pubDate>Fri, 27 Jun 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511). Under the terms of the agreement, Mabwell will grant Qilu Pharmaceutical exclusive rights to develop, manufacture, improve, utilize and commercialize the licensed product in the Greater China (including Chinese Mainland, Hong Kong, Macau and Taiwan). T-m</description>
</item>
<item>
<title>Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-receives-nmpa-approval-albipagrastim-140000815</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-receives-nmpa-approval-albipagrastim-140000815</guid>
<pubDate>Fri, 30 May 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name: MAILISHENG, R&D code: 8MW0511) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing approval by National Medical Products Administration (NMPA). MAILISHENG is Mabwell's first commercialized innovative drug, and is the first launched novel granulocyte colony-stimulating factor (G-CSF) developed with albumin lon</description>
</item>
<item>
<title>Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-clinical-data-multiple-140000719</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-announces-clinical-data-multiple-140000719</guid>
<pubDate>Fri, 23 May 2025 14:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clinical study data of 9MW2821 (Bulumtatug Fuvedotin, BFv), a novel Nectin-4 targeting ADC, in combination with Toripalimab in locally advanced or metastatic uroepithelial carcinoma to be presented as oral presentation, and clinical study data of 7</description>
</item>
<item>
<title>Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting</title>
<link>https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-releases-6-study-results-120000223</link>
<guid isPermaLink="true">https://6ix.com/company/mabwell-shanghai-bioscience-co-ltd-a/news/mabwell-releases-6-study-results-120000223</guid>
<pubDate>Wed, 30 Apr 2025 12:00:00 GMT</pubDate>
<description>Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in poster format at the American Association for Cancer Research (AACR) annual meeting, held from April 25 to 30, 2025.</description>
</item>
</channel>
</rss>